Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

Abstract

AbstractBackgroundThe post‐remission therapy (PRT) choices for adult t(8;21) acute myeloid leukemia (AML) in first complete remission (CR1) need to be further explored.AimsWe aimed to investigate the impact of measurable residual disease (MRD) combined with CD19 on PRT choices for adult t(8;21) AML in CR1.MethodsA total of 150 t(8;21) AML patients were enrolled, including 67 underwent chemotherapy (CMT) and 83 allogeneic hematopoietic stem cell transplantation (allo‐SCT) as PRT in CR1. Subgroup analyses were performed according to MRD level after three cycles of chemotherapy combined with CD19 expression.ResultsMultivariate analysis indicated MRDhigh after three courses of treatment (HR, 0.14 [95% CI, 0.03–0.66]; p = 0.013) and CD19 negativity (HR, 0.14 [95% CI, 0.02–0.96]; p = 0.045) were risk factors for relapse, while allo‐SCT was protective factor for relapse (HR, 0.34 [95% CI, 0.15–0.75]; p = 0.008). Grouped by MRD after three courses of chemotherapy, allo‐SCT had lower CIR (p < 0.001) and better OS (p = 0.003) than CMT for MRDhigh patients, CMT showed a higher CIR (35.99% vs. 15.34%, p = 0.100) but comparable OS (p = 0.588) than allo‐SCT for MRDlow patients. Grouped by CD19 expression, allo‐SCT demonstrated lower CIR (p < 0.001) and better OS (p = 0.002) than CMT for CD19− patients. CMT had a higher CIR (41.37% vs. 10.48%, p = 0.007) but comparable OS (p = 0.147) than allo‐SCT for CD19+ patients. Grouped by MRD combined with CD19, MRDhigh/CD19+ subsets were identified out of CD19+ patients benefiting from allo‐SCT with lower CIR (p = 0.002) and superior OS (p = 0.020) than CMT. CMT preserved comparable CIR (p = 0.939) and OS (p = 0.658) with allo‐SCT for MRDlow/CD19+ patients. MRDlow/CD19− subsets were also identified from MRDlow patients requiring allo‐SCT with lower CIR (p < 0.001) and superior OS (p = 0.008) than CMT. Allo‐SCT maintained lower CIR (p < 0.001) and superior OS (p = 0.008) than CMT for MRDhigh/CD19− patients.ConclusionsMRD combined with CD19 might optimize PRT choices for adult t(8;21) AML patients in CR1.